The receptor mediated active targeting of GBM can be achieved by modifying the nanocarriers surface with ligands such as insulin, transferrin, lactoferrin, amino acids and angiopep-2 etc. [[313], [314], [315], [316], [317], [318], [319]]. This evidence concerns the gene TF and glioblastoma.